Evidence map›Paper›PMID 34252090›Full record

ArticlePloS one2021

Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration.

Amir-Houshang Omidvari, Iris Lansdorp-Vogelaar, Harry J de Koning, Reinier G S Meester

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Health-related Quality of Life using the EQ-5D-5L: normative utility scores in a Dutch female population.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amir-Houshang OmidvariDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-5005-8038
Iris Lansdorp-VogelaarDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Harry J de KoningDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-4682-3646
Reinier G S MeesterDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.

Funding

Comparative Modeling of Effective Policies for Colorectal Cancer ControlU01CA253913 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUTTER, CAROLYN M, ZAUBER, ANN GRAHAM · 2020 to 2025
$6.5M
Controlling Esophageal Cancer: A Collaborative Modeling ApproachU01CA199336 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2015 to 2019
$5.9M
Comparative Modeling of Colorectal Cancer: Informing Health Policies and Prioritizing Future ResearchU01CA199335 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KUNTZ, KAREN M, LANSDORP-VOGELAAR, IRIS · 2015 to 2019
$5.5M
Controlling Esophageal Cancer in the US.: A Colloraborative Modeling ProjectU01CA152926 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2010 to 2014
$3.9M
NCI NIH HHS U01 CA152926NCI NIH HHS U01 CA199335NCI NIH HHS U01 CA199336NCI NIH HHS U01 CA253913
6 · The paper itself

Abstract

introductionIn cost-effectiveness analyses, the future costs, disutility and mortality from alternative causes of morbidity are often not completely taken into account. We explored the impact of different assumed values for each of these factors on the cost-effectiveness of screening for colorectal cancer (CRC) and esophageal adenocarcinoma (EAC).

methodsTwenty different CRC screening strategies and two EAC screening strategies were evaluated using microsimulation. Average health-related expenses, disutility and mortality by age for the U.S. general population were estimated using surveys and lifetables. First, we evaluated strategies under default assumptions, with average mortality, and no accounting for health-related costs and disutility. Then, we varied costs, disutility and mortality between 100% and 150% of the estimated population averages, with 125% as the best estimate. Primary outcome was the incremental cost per quality-adjusted life-year (QALY) gained among efficient strategies.

resultsThe set of efficient strategies was robust to assumptions on future costs, disutility and mortality from other causes of morbidity. However, the incremental cost per QALY gained increased with higher assumed values. For example, for CRC, the ratio for the recommended strategy increased from $15,600 with default assumptions, to $32,600 with average assumption levels, $61,100 with 25% increased levels, and $111,100 with 50% increased levels. Similarly, for EAC, the incremental costs per QALY gained for the recommended EAC screening strategy increased from $106,300 with default assumptions to $198,300 with 50% increased assumptions. In sensitivity analyses without discounting or including only above-average expenses, the impact of assumptions was relatively smaller, but best estimates of the cost per QALY gained remained substantially higher than default estimates.

conclusionsAssumptions on future costs, utility and mortality from other causes of morbidity substantially impact cost-effectiveness outcomes of cancer screening. More empiric evidence and consensus are needed to guide assumptions in future analyses.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overCause of DeathColorectal NeoplasmsComputer SimulationCost-Benefit AnalysisEarly Detection of CancerEsophageal NeoplasmsFemaleForecastingHealth Care CostsHumansMaleMiddle Aged

Identifiers

PMID34252090
PMCPMC8274850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.